Levetiracetam is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow) and 750 mg (orange) tablets.
Levetiracetam tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
Media Articles Related to Levetiracetam
Cannabis compound may halve seizures for patients with severe epilepsy
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2017.04.19]
Cannabidiol - an active component of cannabis - more than halved the frequency of atonic seizures for patients with severe epilepsy, a new study reveals.
Pot Ingredient Might Ease Severe Epilepsy
Source: MedicineNet Seizure Specialty [2017.04.19]
Title: Pot Ingredient Might Ease Severe Epilepsy
Category: Health News
Created: 4/18/2017 12:00:00 AM
Last Editorial Review: 4/19/2017 12:00:00 AM
Study finds genetic basis for drug response in childhood absence epilepsy
Source: Epilepsy News From Medical News Today [2017.04.18]
Consider two children who have childhood absence epilepsy (CAE), the most common form of pediatric epilepsy.
NeuroBreak: Zika Epilepsy; Opioid Beliefs
Source: MedPage Today Psychiatry [2017.04.18]
(MedPage Today) -- News and commentary from the world of neurology and neuroscience
Epilepsy: Another Potential Zika Threat to Babies
Source: MedicineNet Birth Defects Specialty [2017.04.18]
Title: Epilepsy: Another Potential Zika Threat to Babies
Category: Health News
Created: 4/17/2017 12:00:00 AM
Last Editorial Review: 4/18/2017 12:00:00 AM
Published Studies Related to Levetiracetam
Levetiracetam in the treatment of alcohol dependence: toward the end of the
that levetiracetam may be efficient in alcohol-related disorder... CONCLUSIONS: By conducting a state-of-the-art randomized-controlled clinical
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam
extended-release in very heavy drinking alcohol-dependent patients. 
population of very heavy drinkers... CONCLUSIONS: This multisite clinical trial showed no efficacy for levetiracetam
Double-masked, placebo-controlled study of intravenous levetiracetam for the
treatment of status epilepticus and acute repetitive seizures in dogs. 
BACKGROUND: Status epilepticus (SE) and acute repetitive seizures (ARS) are
common canine neurologic emergencies...
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. [2011.07]
BACKGROUND: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease... CONCLUSIONS: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. (c) 2011 Movement Disorder Society. Copyright (c) 2011 Movement Disorder Society.
The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. [2011.07]
Levetiracetam is an anticonvulsant which is assumed to act by modulating neurotransmitter release via binding to the vesicle protein SV2A. This could have an impact on signaling in the nociceptive system, and a pilot study indicated relief of neuropathic pain with levetiracetam. OBJECTIVES: The aim of this study was to test the analgesic effect of levetiracetam in painful polyneuropathy... CONCLUSION: This study indicates that the anticonvulsant levetiracetam has no clinically relevant effect on painful polyneuropathy. Copyright (c) 2010 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.
Clinical Trials Related to Levetiracetam
An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy [Completed]
The purpose of this study is to evaluate the efficacy of Levetiracetam (LEV) used as
monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in
the LEV 1000 mg/day to 2000 mg/day group, in newly or recently diagnosed Epilepsy subjects.
Levetiracetam to Prevent Post-Traumatic Epilepsy [Completed]
Head injury is the cause of approximately 5% of all epilepsy in the US. Past attempts at
preventing epilepsy by treatment with older antiepileptic drugs have been unsuccessful.
Levetiracetam is a novel AED with potent antiepileptogenic properties in animal models of
epilepsy. It has a favorable side effect and pharmacokinetic profile. It is therefore a
strong candidate for a clinical trial of epilepsy prevention following traumatic brain
injury (TBI). However, there has been no experience in administering levetiracetam rapidly
to individuals with acute TBI. The investigators propose to initiate the evaluation of
levetiracetam in prevention of post-traumatic epilepsy by determining the safety,
tolerability, pharmacokinetics and feasibility of acute and chronic administration of
levetiracetam to individuals with head injury with a high risk for developing post-traumatic
epilepsy. Further, the investigators will follow subjects for 2 years after injury in order
to obtain pilot data about effect of levetiracetam on PTE. This pilot study is the first
step in evaluation of levetiracetam in prevention of post-traumatic epilepsy.
Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients [Completed]
This is a human pharmacology, single-dose study to investigate the pharmacokinetics of
orally administered Levetiracetam (LEV) in Japanese subjects with normal renal function and
in Japanese subjects with various degrees of impaired renal function.
Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-Maintained Patients. [Active, not recruiting]
The proposed investigation will use methadone maintained patients who have concurrent
cocaine dependence in order to take advantage of the excellent (over 80%) treatment
retention in this patient group and to maximize treatment compliance by daily observed
medication with both methadone and levetiracetam. In the initial patients we will explore
the tolerability of escalating doses of levetiracetam as well as its potential role in
reducing cocaine use, as monitored by self-report and verified by three-times weekly urine
toxicology testing in methadone treated patients. The specific aim of this study is to
evaluate the tolerability and efficacy of levetiracetam 3 grams/day in modifying
cocaine-using behavior, reducing cocaine craving and attenuating cocaine's reinforcing
effect among methadone-maintained patients
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese [Completed]
The part A of N01362 is to evaluate the bioequivalence of Levetiracetam (LEV) 1500 mg
intravenous (iv) infusion when compared to tablet oral administration in Chinese healthy
Reports of Suspected Levetiracetam Side Effects
Product Substitution Issue (61),
Drug Ineffective (60),
Condition Aggravated (59),
Grand MAL Convulsion (46),
Petit MAL Epilepsy (40),
Maternal Exposure During Pregnancy (39), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Levetiracetam has an overall score of 3. The effectiveness score is 8 and the side effect score is 2. The scores are on ten point scale: 10 - best, 1 - worst.
Levetiracetam review by 50 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Extremely Severe Side Effects|
|Condition / reason:|| || right temporal lobe epilepsy|
|Dosage & duration:|| || 4000 daily (dosage frequency: 2000 mg. twice a day) for the period of I have been taking it for 9 mths.|
|Other conditions:|| || hypothyroid, Atrial-Fib,Stroke-April '06|
|Other drugs taken:|| || syntroid, valium, coumadin, atenolol|
|Benefits:|| || In the beginning my seizures seemed to decrease, however at the time I was also on Depakote and Diamox as well as valium for right temporal lobe epilepsy; my doctor added keppra before he started weaning me off the depakote and diamox. I was feeling a lot better on all those meds. Then just the Keppra.|
|Side effects:|| || Side effects= Intermittent Headaches,weakness,shaky and Double Vision, poor muscle coordination, problem with movement, walking, Abnormal Gait, behavioral changes, anger,weight loss, slurred speech, & memory loss.|
|Comments:|| || I started on Keppra in Feb. '09, at first I thought it was the miracle drug. Boy was I wrong! At the time I was also on Depakote, Diamox and valium. First the Doctor added Keppra and began weaning me off the Depakote ER 500mg pm. 250mg. am. It took awhile to get off Depakote because I kept having effects from being weaned off it after being on it for 25 years. Then a few months later he started to wean me off of diamox, which I stopped a week ago, after a long process of being weaned off that drug. Now on Keppra alone with valium, I feel horrible and no heip from my Neurologist. I feel completely alone and with no help in sight!|
Page last updated: 2017-04-19